SanBio Company Limited (4592.T)
JPY 2299.0
(-0.99%)
JPY 2299.0
(-0.99%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.53 Billion JPY | -42.54% |
| 2022 | 7.89 Billion JPY | 19.31% |
| 2021 | 6.62 Billion JPY | 14.12% |
| 2020 | 5.8 Billion JPY | -2.22% |
| 2019 | 5.93 Billion JPY | 32.57% |
| 2018 | 4.47 Billion JPY | -8.08% |
| 2017 | 4.86 Billion JPY | 69.97% |
| 2016 | 2.86 Billion JPY | 24.55% |
| 2015 | 2.29 Billion JPY | 134.57% |
| 2014 | 980.46 Million JPY | 24.34% |
| 2013 | 788.52 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 905.34 Million JPY | 36.32% |
| 2024 Q1 | 664.14 Million JPY | -18.22% |
| 2023 Q4 | 812.06 Million JPY | 26.82% |
| 2023 Q3 | 640.32 Million JPY | -60.55% |
| 2023 Q1 | 1.46 Billion JPY | -2.23% |
| 2023 FY | 4.52 Billion JPY | -42.71% |
| 2023 Q2 | 1.62 Billion JPY | 11.04% |
| 2022 Q4 | 1.49 Billion JPY | -16.1% |
| 2022 Q2 | 2.77 Billion JPY | 50.59% |
| 2022 FY | 7.89 Billion JPY | 19.31% |
| 2022 Q1 | 1.84 Billion JPY | -1.95% |
| 2022 Q3 | 1.78 Billion JPY | -35.84% |
| 2021 Q4 | 1.88 Billion JPY | 11.5% |
| 2021 FY | 6.62 Billion JPY | 14.12% |
| 2021 Q1 | 1.54 Billion JPY | -4.53% |
| 2021 Q2 | 1.51 Billion JPY | -1.8% |
| 2021 Q3 | 1.68 Billion JPY | 11.54% |
| 2020 Q2 | 1.32 Billion JPY | 6.96% |
| 2020 Q4 | 1.61 Billion JPY | -0.25% |
| 2020 Q3 | 1.61 Billion JPY | 21.72% |
| 2020 FY | 5.8 Billion JPY | -2.22% |
| 2020 Q1 | 1.24 Billion JPY | -33.93% |
| 2019 FY | 5.93 Billion JPY | 32.57% |
| 2019 Q4 | 1.88 Billion JPY | 51.6% |
| 2019 Q3 | 1.24 Billion JPY | -9.79% |
| 2019 Q2 | 1.37 Billion JPY | -4.42% |
| 2019 Q1 | 1.43 Billion JPY | 0.77% |
| 2018 Q4 | 1.42 Billion JPY | 40.37% |
| 2018 Q3 | 1.01 Billion JPY | 17.05% |
| 2018 Q2 | 868.68 Million JPY | -25.29% |
| 2018 Q1 | 1.16 Billion JPY | -12.46% |
| 2018 FY | 4.47 Billion JPY | -8.08% |
| 2017 Q3 | 1.14 Billion JPY | -8.92% |
| 2017 Q1 | 1.14 Billion JPY | 28.46% |
| 2017 FY | 4.86 Billion JPY | 69.97% |
| 2017 Q4 | 1.32 Billion JPY | 16.35% |
| 2017 Q2 | 1.25 Billion JPY | 9.41% |
| 2016 Q3 | 678.07 Million JPY | -9.15% |
| 2016 Q4 | 891.79 Million JPY | 31.52% |
| 2016 FY | 2.86 Billion JPY | 24.55% |
| 2016 Q2 | 746.36 Million JPY | 36.1% |
| 2016 Q1 | 548.37 Million JPY | -13.51% |
| 2015 Q3 | 698.91 Million JPY | 16.35% |
| 2015 FY | 2.29 Billion JPY | 134.57% |
| 2015 Q1 | 366.24 Million JPY | 34.48% |
| 2015 Q2 | 600.68 Million JPY | 64.01% |
| 2015 Q4 | 634.04 Million JPY | -9.28% |
| 2014 FY | 980.46 Million JPY | 24.34% |
| 2014 Q4 | 272.35 Million JPY | 0.0% |
| 2013 FY | 788.52 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -253.374% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -686.907% |
| GNI Group Ltd. | 9.32 Billion JPY | 51.31% |
| Linical Co., Ltd. | 2.7 Billion JPY | -67.788% |
| Trans Genic Inc. | 2.15 Billion JPY | -110.156% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -204.394% |
| Soiken Holdings Inc. | 3.07 Billion JPY | -47.799% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -144.43% |
| AnGes, Inc. | 8.9 Billion JPY | 49.013% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -381.295% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 76.347% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -999.058% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -365.361% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -76.782% |
| CanBas Co., Ltd. | 278 Million JPY | -1532.734% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -297.622% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -149.677% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -183.022% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -91.191% |
| PeptiDream Inc. | 9.68 Billion JPY | 53.145% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -131.512% |
| Ribomic Inc. | 1.1 Billion JPY | -310.513% |
| Healios K.K. | 3.48 Billion JPY | -30.169% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -293.076% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -240.136% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -223.414% |
| StemRIM | 2.07 Billion JPY | -118.642% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -131.169% |
| FunPep Company Limited | 313.82 Million JPY | -1346.366% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -373.794% |
| Stella Pharma Corporation | 963.98 Million JPY | -370.858% |
| TMS Co., Ltd. | 943.25 Million JPY | -381.207% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -316.44% |
| Cuorips Inc. | 598.11 Million JPY | -658.88% |
| K Pharma,Inc. | 543.94 Million JPY | -734.464% |
| Takara Bio Inc. | 23.9 Billion JPY | 81.012% |
| ReproCELL Incorporated | 1.51 Billion JPY | -199.799% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -283.365% |
| StemCell Institute Inc. | 1.16 Billion JPY | -290.579% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -198.172% |
| CellSeed Inc. | 804.93 Million JPY | -463.899% |